Is HER2 targeting on the horizon for urothelial carcinoma?

touchFOCUS for touchONCOLOGY

A genitourinary medical oncologist considers the potential for targeting HER2 in the treatment of urothelial carcinoma, including the rationale for HER2 as a target, approaches to HER2 testing, the latest data on emerging HER2-targeted therapies and the potential implications for future clinical practice. 

The expert:

• Dr Vadim Koshkin - University of California San Francisco, CA, USA
  

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Seagen Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com